歐康維視生物-B(01477.HK)與暉致合作分銷及推廣眼科藥物
格隆匯3月1日丨歐康維視生物-B(01477.HK)發佈公吿,2022年3月1日,集團與暉致醫藥有限公司(暉致中國,美國Viatris Inc.的中國聯屬公司)達致一系列的合作安排,據此,集團成為獨家推廣公司,負責在中國大陸醫院推廣及推銷暉致兩款眼科藥物,分別為適利達及適利加,並向暉致中國收取推廣服務費。
該項推廣安排的初始期限為2022年3月1日起至2026年12月31日,附帶有條件自動續期條款。另一方面,暉致中國成為獨家分銷商,負責在中國大陸的院外分銷及零售藥物市場分銷、推廣及推銷公司的玻璃酸鈉滴眼液,並於一段期間內向集團收取相關費用。該項分銷安排的初始期限為2022年3月1日起至2026年12月31日,附帶有條件自動續期條款。除上述費用外,雙方根據合作安排將不會產生其他費用或收費。
公吿表示,與暉致中國達成合作安排將能夠把握有關合作在中國大陸業務發展方面帶來的若干協同效應。通過與暉致中國合作,集團獲得了推廣權,可在中國大陸醫院推廣目前治療青光眼及降低眼內壓的一線藥物,從而拓展其管線並增強集團整體的銷售表現及提升其於中國大陸公立醫院的銷售覆蓋。此外,暉致為一家備受認可且世界知名的製藥公司。公司相信,暉致中國在零售推廣方面(包括但不限於市場滲透力及不同的銷售渠道)的雄厚實力,將推動集團進一步加快開拓市場及提升品牌知名度;此外,與暉致中國達成的合作安排亦將進一步使集團能與該世界知名的製藥公司建立長期而穩固的合作關係,對於公司未來的業務佈局將會有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.